

## Latvia

### Recent and planned developments in pharmaceutical policies 2017/2018

#### Special topic: patient involvement in pricing and reimbursement of medicines

##### CHANGES IN PRICING

No changes

##### CHANGES IN REIMBURSEMENT

- 09/01/2018: reimbursement rate for psoriasis, Crohn disease and ulcerative colitis increased from 75% to 100%

##### OTHERS CHANGES

No changes

#### SPECIAL TOPIC: Patient Involvement in Pricing and Reimbursement of Medicines

- No formal and direct involvement of patients in HTA or decision making on pricing and reimbursement of medicines
- Patients and patients' organizations can express their interest in reimbursement of new medicines (meetings, support letters) but in reality the decision on reimbursement depends on political will to allocate the financing necessary for the reimbursement of these medicines
- Representatives of patients' organizations are involved in discussions on topics related to development of healthcare policy in Latvia (Advisory Board in the Field of Pharmacy, Strategic Council of the Health Sector, Commission for the Coordination of the Prevention of HIV Infection, Tuberculosis and Sexual Transmission Infections, Working Group on Development of the Plan of Rear Diseases, etc.)